Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes | Zendy

Elza Muscelli | Zendy; A Casolaro | Zendy; Amalia Gastaldelli | Zendy; Andrea Mari | Zendy; Giuseppe Seghieri | Zendy; Brenno Astiarraga | Zendy; Yu Chen | Zendy; Maria Alba | Zendy; Jens J. Holst | Zendy; Ele Ferrannini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes

Author(s) -

Elza Muscelli,

A Casolaro,

Amalia Gastaldelli,

Andrea Mari,

Giuseppe Seghieri,

Brenno Astiarraga,

Yu Chen,

Maria Alba,

Jens J. Holst,

Ele Ferrannini

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-1205

Subject(s) - medicine , incretin , sitagliptin , endocrinology , type 2 diabetes , glycemic , insulin , area under the curve , diabetes mellitus , glycated hemoglobin , context (archaeology) , placebo , glucagon , meal , glucagon like peptide 1 , biology , paleontology , alternative medicine , pathology

Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes. The underlying mechanisms (incretin effect, β-cell function, endogenous glucose production) are not well known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research